Short QT Syndrome (SQTS)
Details
Short QT syndrome is a rare autosomal dominant channelopathy characterised by accelerated cardiac repolarization producing a QTc ≤360 ms (or ≤320 ms as a standalone diagnostic criterion). Eight genetic subtypes are defined, predominantly caused by gain-of-function mutations in potassium channel genes (KCNH2, KCNQ1, KCNJ2) or loss-of-function mutations in calcium channel subunits (CACNA1C, CACNB2, CACNA2D1). The syndrome predisposes to atrial fibrillation, ventricular fibrillation, and sudden cardiac death — approximately 30% of patients present with SCA/SCD as the first clinical manifestation. Variant detection rates are low (~20–25%), and a broad list of acquired phenocopies must be excluded before a hereditary diagnosis is made.
Key Facts
Epidemiology and Genetics
- Prevalence: 0.02–0.1% of adults; male predominance; low penetrance. (sources/channelopathies-jaha-2025, rating: high)
- Only just over 200 patients have been reported worldwide, so prevalence and natural history are largely inferred; the two largest cohorts remain the basis of most clinical statements. (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
- 8 subtypes: SQT1–3 caused by gain-of-function mutations in K⁺ channel genes (KCNH2, KCNQ1, KCNJ2); SQT4–6 by loss-of-function in Ca²⁺ channel subunits (CACNA1C, CACNB2, CACNA2D1); SQT7 by SCN5A R689H loss-of-function; SQT8 by SLC4A3 loss-of-function affecting Cl⁻/HCO₃⁻ exchange. (sources/channelopathies-jaha-2025)
- The calcium-channel subtypes are weak evidence: CACNA1C/CACNB2/CACNA2D1 variants have been described in patients with short QTc or a combined short-QT/Brugada phenotype, but causality is limited. The SLC4A3 AE3 missense was found in one large family and a smaller unrelated family — the strongest non-potassium evidence. (sources/inherited-arrhythmias-nrdp-2020)
- ClinGen-curated core genes (4 genes): KCNH2 (definitive), KCNQ1 (moderate), KCNJ2 (moderate), SLC4A3 (moderate). SLC4A3 encodes the cardiac chloride-bicarbonate exchanger AE3; loss-of-function causes reduced sarcolemmal localisation → intracellular alkalinisation → shortened AP duration. Two families identified with the identical SLC4A3 variant to date. (sources/arrhythmia-genetics-mgenetik-2025, rating: high)
- Variant detection rate: ~20–25% in index patients. A confirmed pathogenic variant (ACMG class 4/5) scores 2 points in the Gollob diagnostic score. (sources/arrhythmia-genetics-mgenetik-2025)
- Clinical outcomes: ~30% of SQTS patients have SCA/SCD as the first clinical manifestation. Life-threatening arrhythmias occur equally across genotypes. Syncope is more frequent in males; atrial arrhythmias (AF, flutter, palpitations) are distributed equally by sex. (sources/arrhythmia-genetics-mgenetik-2025)
The two largest cohorts
- European Short QT Registry (n=53): 75% male, median age 23, follow-up 64 ± 27 months; 62% symptomatic at presentation, most commonly cardiac arrest (33%); >90% of arrests occurred between ages 14 and 40; 24% had palpitations, with AF or flutter documented in six; 15% had syncope. AF was already present in newborns and young children. (sources/inherited-arrhythmias-nrdp-2020)
- Second cohort (n=73): 84% male, mean age 26 ± 15, follow-up 60 ± 41 months; 53% symptomatic; SCD or non-fatal cardiac arrest in 40% and syncope in 19%; cardiac arrest in 4% during the first year of life. Annual event rate 1.3% between ages 20 and 40, with 40% experiencing a cardiac arrest by age 40 (cumulative annual event rate 0.9%). No trigger was identified and 83% of arrests occurred at rest. (sources/inherited-arrhythmias-nrdp-2020)
- SQTS belongs to the spectrum of early repolarization syndrome. (sources/channelopathies-jaha-2025)
Pathophysiology — Subtypes and Mechanisms
- Core gain-of-function mechanism (SQT1–3): Increased outward K⁺ currents — IKr (KCNH2/SQT1), IKs (KCNQ1/SQT2), IK1 (KCNJ2/SQT3) — accelerate the action potential plateau and shorten the absolute refractory period, reducing repolarization reserve and creating a re-entrant arrhythmia substrate. (sources/channelopathies-jaha-2025, rating: high)
- Loss-of-function calcium channel subtypes (SQT4–6): Reduced inward ICa,L via CACNA1C, CACNB2, or CACNA2D1 loss-of-function also abbreviates the AP plateau. These subtypes show phenotypic overlap with Brugada syndrome — particularly CACNA1C and CACNB2 variants, which may present with combined SQTS/BrS overlap features. (sources/channelopathies-jaha-2025)
- SLC4A3/SQT8: Loss-of-function reduces sarcolemmal AE3 exchanger → impaired Cl⁻/HCO₃⁻ exchange → intracellular alkalinisation → net AP shortening. Mechanistically distinct from all ion channel subtypes. (sources/arrhythmia-genetics-mgenetik-2025)
ECG Features
- Characteristic morphology: Short or absent ST segments; asymmetrical T-waves with high amplitude and prolonged Tpeak-to-T-end (TpTe) interval. The tall, narrow T-wave and abbreviated ST segment are visually distinctive. (sources/repolarisation-jaccep-2023, rating: high)
- Supporting ECG features in the Primer: PQ-segment deviation (81% of patients), tall symmetrical T waves with a very short or absent ST segment, early repolarisation (65%), frequent apparent U waves (especially precordial) and impaired QT adaptation during exercise. (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
- Measure the QT at a heart rate of 50–70 bpm, because QT adaptation to rate is impaired in SQTS and a tachycardia or bradycardia tracing will mislead. (sources/inherited-arrhythmias-nrdp-2020)
- Risk markers within SQTS: Symptomatic patients (SCA survivors) show shorter J-point-to-T-peak intervals and a higher TpTe/QTc ratio than asymptomatic patients. Elevated TpTe/QTc reflects increased transmural dispersion of repolarization — the functional arrhythmogenic substrate. (sources/repolarisation-jaccep-2023)
- QTc severity does not predict arrhythmic risk in SQTS — unlike LQTS, the magnitude of QTc shortening does not stratify cardiac event probability. Risk stratification must rely on clinical history, family history, and structural assessment rather than QTc alone. (sources/repolarisation-jaccep-2023)
Diagnosis
- ESC 2022 Class I criteria:
- QTc ≤360 ms plus ≥1 of: (a) pathogenic mutation, (b) family history of SQTS, (c) VT/VF survival without structural heart disease
- ESC 2022 Class IIa criteria:
- QTc ≤320 ms alone: consider SQTS
- QTc 320–360 ms + arrhythmic syncope: consider SQTS
- (sources/VA-SCD-ESC-2022, rating: very high)
- The 2015 ESC thresholds the 2022 criteria build on: QTc ≤340 ms is Class I (level C); QTc ≤360 ms with a pathogenic variant, family history of SQTS, family history of SCD <40 years or documented VT/VF without structural disease is Class IIa (level C). (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
- Short QT alone is not a risk marker. QTc <340 ms occurs in 0.4% of a Finnish population cohort and <320 ms in 0.1%; QTc ≤340 ms in 0.05% of children. Population studies found no increased arrhythmic risk from a short interval by itself, which is why the diagnostic threshold requires a second feature. (sources/inherited-arrhythmias-nrdp-2020)
- Gollob diagnostic score — key domains: QTc ≤370 ms (1 pt), ≤350 ms (2 pts), ≤330 ms (3 pts); J-point-to-T-peak interval <120 ms (1 pt); clinical history (VF/pVT 2 pts, unexplained syncope 1 pt, AF 1 pt); family history of SQTS or sudden death <40 years (1 pt); pathogenic mutation (2 pts). Also reported as the Schwartz SQTS score; interpretation ≤2 low, 3 intermediate, ≥4 high, and at least one ECG finding is required before clinical, family or genetic points count. (sources/arrhythmia-genetics-mgenetik-2025; sources/channelopathies-jaha-2025)
- Genetic testing: Class I (ESC 2022). (sources/VA-SCD-ESC-2022)
- ILR in young SQTS patients: Class IIa (ESC 2022). (sources/VA-SCD-ESC-2022)
- PES for SCD risk stratification: NOT recommended (Class III) — programmed electrical stimulation has not been validated for arrhythmic risk stratification in SQTS (unlike its Class IIb role in Brugada syndrome). (sources/VA-SCD-ESC-2022)
- Acquired phenocopies and exogenous causes to exclude before hereditary diagnosis:
- Electrolyte/metabolic: hyperkalemia, hypercalcemia, acidosis, primary hyperparathyroidism, congenital adrenal hyperplasia, hyperthyroidism, milk-alkali syndrome, vitamin A intoxication
- Systemic/genetic: congenital lactase deficiency, primary carnitine deficiency (SLC22A5), Klinefelter syndrome (47,XXY)
- Iatrogenic/toxic: digitalis intoxication, hyperthermia, ATP K⁺ channel openers (pinacidil, levcromakalim), rufinamide (anti-convulsant)
- (sources/arrhythmia-genetics-mgenetik-2025)
Management
- ICD: Primary therapy for symptomatic patients with life expectancy >30 years. Class I after SCA or documented sustained VT/VF (ESC 2022). (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- The main predictor of recurrence is a prior non-fatal cardiac arrest, with an estimated 10% per year risk of recurrent arrest in patients with prior arrest or documented spontaneous sustained VT — the basis for secondary-prevention ICD. (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
- Asymptomatic patients with QTc 300–360 ms are monitored without prophylactic medication. QTc ≤300 ms may carry increased SCD risk, especially during sleep or rest. (sources/inherited-arrhythmias-nrdp-2020)
- Quinidine: First-line pharmacotherapy; prolongs QTc via IKr blockade. Hydroquinidine shares this mechanism. Effective in SQTS1. ESC 2022 Class IIb — when ICD is contraindicated/refused, or in asymptomatic patients with a family history of SCD. (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- Quinidine is the only drug that lengthens QTc and reduces arrhythmic events, and it prevents further ICD discharges in patients with recurrent shocks; it may be used for primary prevention case-by-case in high-risk families (IIb C), and considered when an ICD is refused. (sources/inherited-arrhythmias-nrdp-2020)
- Amiodarone and sotalol: ineffective in SQTS1 despite being IKr blockers — gain-of-function KCNH2 mutation alters drug-channel binding kinetics, preventing effect. This genotype-drug interaction is mechanistically important; see Contradictions. (sources/channelopathies-jaha-2025)
- Isoproterenol for electrical storm: Class IIb (ESC 2022). (sources/VA-SCD-ESC-2022)
- Emergency isoprenaline can restore and maintain sinus rhythm in electrical storm or refractory VF, an effect consistent with the need to restore plateau current. (sources/inherited-arrhythmias-nrdp-2020)
- Pharmacological data are limited and primarily focused on SQTS1; genotype-targeted drug research for SQT2–8 is an unmet need. (sources/channelopathies-jaha-2025)
Contradictions / Open Questions
- Amiodarone/sotalol paradox in SQTS1: Despite both being IKr blockers, amiodarone and sotalol are clinically ineffective in SQTS1 — whose primary pathogenesis is KCNH2 gain-of-function. The gain-of-function mutation alters drug-channel binding kinetics so that standard IKr-blocking drugs cannot exert their expected effect. This mechanistic exception undermines the assumption that channel-blocking drugs reliably reverse channel gain-of-function, a lesson relevant across channelopathies. (sources/channelopathies-jaha-2025)
- SupRep for SQTS1 — silencing without replacement: Gene therapy for SQTS1 requires only shRNA silencing of the gain-of-function KCNH2 allele, with no replacement cDNA needed — the opposite of the SupRep approach for LQT2 (where silencing is followed by replacement). Over-silencing KCNH2 in a SQTS1 patient risks inducing iatrogenic LQT2. The therapeutic window for silencing-only has not been established in humans. (sources/gene-therapy-arrhythmia-2025)
- ESC 2022 diagnostic threshold expansion: ESC 2022 expanded SQTS diagnosis to QTc ≤360 ms with additional criteria (vs. the prior QTc <340 ms threshold). This broader definition captures more patients but may reduce specificity — a healthy individual with borderline short QTc can now qualify with a single additional feature such as a family history of unexplained sudden death, which itself may be undiagnosed SQTS. The net sensitivity/specificity of the revised criteria has not been prospectively validated. (sources/VA-SCD-ESC-2022, sources/channelopathies-jaha-2025)
- PRS entirely unstudied in SQTS: Common variant genetic modifiers of SQTS susceptibility or severity have not been investigated. By analogy with LQTS, QTc-shortening common variants may modulate SQTS penetrance and severity — but this awaits dedicated investigation. (sources/repolarisation-jaccep-2023)
- The trigger for polymorphic VT is unexplained. AP abbreviation, dispersion and wavelength shortening establish the substrate, but no clear mechanism accounts for the PVC that actually precipitates polymorphic VT in SQTS — unlike LQTS (EAD) or CPVT (DAD), where a trigger is defined. (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
- A short QTc is a population trait as well as a disease marker. With QTc <340 ms in 0.4% of adults and no associated arrhythmic risk in unselected cohorts, the diagnostic threshold can only be applied with a second clinical or genetic feature — yet the additional features (family history, mutation) are themselves of uncertain specificity. (sources/inherited-arrhythmias-nrdp-2020)
- Two cohorts, two pictures of the disease. Sixty-two per cent were symptomatic at presentation in the European registry versus 53% in the second cohort; the first emphasised palpitations and AF, the second cardiac arrest. Both are referral series, so the true population phenotype — including asymptomatic incidental cases — remains unknown. (sources/inherited-arrhythmias-nrdp-2020)
Connections
- Related to concepts/Cardiac-Action-Potential
- Related to entities/Long-QT-Syndrome — LQTS diagnostic criteria and Schwartz Score
- Related to concepts/Channelopathies
- Related to concepts/Sudden-Cardiac-Death
- Related to entities/Early-Repolarization-Syndrome
- Related to entities/KCNQ1
- Related to entities/KCNH2
- Related to entities/KCNJ2
- Related to concepts/Electrical-Storm
- Related to concepts/SupRep-Therapy
- Related to concepts/Cardiogenetic-Centers
- Related to concepts/Genetic-Testing-in-Arrhythmias — indication, panel and the ~20–25% detection rate
- Related to concepts/Cardiac-Repolarization
- Related to concepts/Polygenic-Risk-Score
- Related to sources/channelopathies-jaha-2025
- Related to sources/arrhythmia-genetics-mgenetik-2025
- Related to sources/repolarisation-jaccep-2023
- Related to sources/VA-SCD-ESC-2022
- Related to sources/gene-therapy-arrhythmia-2025